Highly Potent Viral Transduction with Travirtide
Travirtide is a synthetic linear peptide that strongly enhances viral transduction, is well soluble and demonstrates low cytotoxicity. It is a potent enhancer of retroviral transduction, providing a more than 7-fold increase in transduction compared to the absence of enhancer at a concentration as low as 1.25 μg/mL. Travirtide is also significantly more potent than other transduction enhancers. For example, to achieve a strong transduction efficacy of more than 55 % GFP-positive cells, we needed a quarter of the amount of Travirtide compared to a well-known competitor product (1.25 vs. 5 μg/mL). At the same time, Travirtide was also more active than a second competitor product.
For detailed data please see our
conference poster.
Travirtide (CGP) - Specifications
- Amount: 1.0 mg net (AAA)
- Purity: Clinical Grade: >95% (HPLC/MS)
- Counterion: chlorid
- Delivery Format: Freeze-dried in Crystal Zenith vial
- MW (average): 1440.73
- Application(s): T-cell immunity
- Condition(s)/Topic(s): Cancer, Gene therapy, Infection
- Standard Delivery Time: 2-5 days
Are you interested in other peptides or conjugation to a protein, nucleic acid or lipid? Choose your sequence, amount and purity with our
Custom Peptide Synthesis services.
Travirtide CGP for Clinical Applications
- CGP &%2361; Clinical Grade Peptide
- manufactured by low bioburden process
- analyzed by high resolution HPLC-MS
- absolutely quantified by AAA
- residual solvent and counter ion determination
- endotoxin and bioburden testing
- reporting of related substances
- certificate of analysis (CoA) delivered
- no preservative needed!
Background of Viral Transduction Enhancers
Gene transfer into T cells, hematopoietic stem cells or other cells via viral vectors is a widely used technique in modern biology laboratories. It can be used in research projects, e.g. the validation of disease targets, as well as in the development of therapeutics for infectious diseases or cancer. One practical example are cellular immunotherapies involving T-cells with chimeric antigen receptors (CAR-Ts) or engineered T-cell receptors (TCR-Ts) have led to promising new cancer treatments. However, due to the complex manufacturing process, these therapies are still very costly. A critical step is gene transfer, which often relies on retroviral vectors and is often hampered by low transduction rates. To address this, a number of transduction enhancers have been developed, but with variable success. These include surfactants, fibril-forming or amphipathic peptides, and coating of cultureware, which is cumbersome due to time-consuming liquid handling steps.
Benefits of JPT’s Transduction Enhancer Travirtide
Travirtide is a highly potent transduction enhancer for viral gene transfer. The peptide is designed to enhance transduction with various retroviral vectors. It promotes viral vector entry into mammalian cells via a rapid and robust protocol. Due to its high potency, it should find wide application in transduction experiments and has the potential to reduce the cost of CAR-T cell production.
